Biocon’s Board of Directors has approved the unaudited financial results for Q2 2025-26. The board also approved the early redemption of 50,000 Non-Convertible Debentures and the acquisition of 1,06,86,044 Compulsorily Convertible Debentures of Biocon Biologics Limited from ESOF III Investment Fund and EAAA India Alternatives Limited. Additionally, the issuance of Commercial Papers up to ₹550 Crores has been approved.
Financial Results for Q2 2025-26
Biocon Limited has announced its unaudited financial results, prepared per Indian Accounting Standards, for the quarter and half-year ended September 30, 2025 (Q2 2025-26). Key highlights from the standalone results include:
- Revenue from operations: ₹5,833 million for Q2 and ₹11,204 million for H1.
- Total Income: ₹7,171 million for Q2 and ₹13,155 million for H1.
- Net Profit: ₹709 million for Q2 and ₹626 million for H1.
Early Redemption of Debentures
The Board has approved the early full redemption of 50,000 unlisted, secured, rated, redeemable Non-Convertible Debentures (NCDs), with a face value of ₹1,00,000 each. This totals ₹500 Crores. The redemption, subject to necessary approvals, is slated for on or before January 31, 2026.
Acquisition of Convertible Debentures
Approval has been granted for the acquisition of 1,06,86,044 Unlisted, Secured, Compulsorily Convertible Debentures (‘CCDs’) of Biocon Biologics Limited (‘BBL’) from ESOF III Investment Fund and EAAA India Alternatives Limited. The face value of these CCDs is ₹10 each, aggregating to ₹300 Crores. The acquisition is planned for on or before January 30, 2026, pending required approvals.
Issuance of Commercial Papers
The board has also authorized the issuance of Commercial Papers up to ₹550 Crores in one or more tranches via private placement.
Source: BSE
